Advertisement
Singapore markets closed
  • Straits Times Index

    3,287.75
    -5.38 (-0.16%)
     
  • S&P 500

    5,009.63
    -62.00 (-1.22%)
     
  • Dow

    37,850.33
    -610.59 (-1.59%)
     
  • Nasdaq

    15,447.69
    -265.06 (-1.69%)
     
  • Bitcoin USD

    63,802.01
    -865.30 (-1.34%)
     
  • CMC Crypto 200

    1,378.18
    -4.39 (-0.32%)
     
  • FTSE 100

    8,075.71
    +35.33 (+0.44%)
     
  • Gold

    2,343.60
    +5.20 (+0.22%)
     
  • Crude Oil

    82.30
    -0.51 (-0.62%)
     
  • 10-Yr Bond

    4.7020
    +0.0500 (+1.07%)
     
  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     
  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     
  • FTSE Bursa Malaysia

    1,569.25
    -2.23 (-0.14%)
     
  • Jakarta Composite Index

    7,155.29
    -19.24 (-0.27%)
     
  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

56% of Analysts Recommend a ‘Buy’ for Editas Medicine

56% of Analysts Recommend a ‘Buy’ for Editas Medicine

In August, the National Institutes of Health’s (or NIH) recombinant DNA advisory committee completed the NIH protocol for Editas Medicine’s (EDIT) EDIT-101. EDIT-101 is an investigational CRISPR genome editing therapy for the treatment of individuals with LCA10 (Leber Congenital Amaurosis type 10). Editas Medicine plans to submit an IND (Investigational New Drug) application to the FDA in October.